Menu

Alfred Alberts, Lovastatin Discoverer, Dies

The Merck biochemist found the compound that led to a popular cholesterol-lowering drug.

Jul 5, 2018
Kerry Grens
Alfred Alberts
MERCK

Alfred Alberts, a biochemist at Merck who discovered a cholesterol-lowering compound that led to the development of a widely used statin, died June 16. He was 87.

“Behind every drug there are heroes,” Michael Brown, a Nobel laureate at the University of Texas Southwestern Medical Center who uncovered key cholesterol-processing steps in cells, tells The New York Times. And Alberts was “an unsung hero.”

Born in 1931 in New York, Alberts studied cell biology, but dropped out of a PhD program at the University of Maryland to take a job at the National Institutes of Health. There, he met his longtime collaborator P. Roy Vagelos in 1959 and began working in his lab. It was the beginning of a life-long partnership.

“He was my right-hand man,” Vagelos tells The Times. “We were more like brothers, like twins.”

In the 1960s, Alberts followed Vagelos to Washington University in St. Louis and, despite not having a PhD or MD, became an associate professor there. A decade later, Vagelos and Alberts moved to Merck and set out to develop a drug that would lower cholesterol. Alberts identified such a compound in a fungus, which eventually was worked into a medicine and approved in 1987.

Alberts was a modest scientist who didn’t get a lot of credit for his contributions, but lovastatin, as the drug came to be named, “[t]hat was Al’s discovery,” Vagelos tells The Times.

Alberts is survived by his wife, three children, and two grandchildren.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.